Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men

European Urology

Volumn 67, Issue 2, 2015, Pages 191-194

  Sigurdardottir, Lara G ^a,b   Markt, Sarah C ^c   Rider, Jennifer R ^c,d   Haneuse, Sebastien ^c   Fall, Katja ^a,c,e   Schernhammer, Eva S ^c,d   Tamimi, Rulla M ^c,d   Flynn Evans, Erin ^d,f   Batista, Julie L ^c,d   Launer, Lenore ^g   Harris, Tamara ^g   Aspelund, Thor ^a,h   Stampfer, Meir J ^c,d   Gudnason, Vilmundur ^a,h   Czeisler, Charles A ^d,f   Lockley, Steven W ^d,f   Valdimarsdottir, Unnur A ^a,c   Mucci, Lorelei A ^a,c,d  

^a UNIVERSITY OF ICELAND   (Iceland)

^b ICELANDIC CANCER SOCIETY   (Iceland)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g NATIONAL INSTITUTE ON AGING   (United States)

^h ICELANDIC HEART ASSOCIATION   (Iceland)

Author keywords

Circadian rhythm; Melatonin levels; Prostate cancer

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; MELATONIN; 6-SULFATOXYMELATONIN; BIOLOGICAL MARKER;

ADVANCED CANCER; AGED; ARTICLE; CANCER RISK; CASE STUDY; COHORT ANALYSIS; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; HIGH RISK POPULATION; HORMONE URINE LEVEL; HUMAN; ICELANDER; INCIDENTAL FINDING; MAJOR CLINICAL STUDY; MALE; MICTURITION; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SLEEP DISORDER; AGE; ANALOGS AND DERIVATIVES; DOWN REGULATION; ICELAND; INCIDENCE; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; RISK FACTOR; SLEEP; SLEEP WAKE DISORDERS; TIME FACTOR; URINE;

AGE FACTORS; BIOMARKERS; DOWN-REGULATION; HUMANS; ICELAND; INCIDENCE; MALE; MELATONIN; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SLEEP; SLEEP WAKE DISORDERS; TIME FACTORS;

EID: 84920699437     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.07.008     Document Type: Article

References (10)

1. D.E. Blask, R.T. Dauchy, and L.A. Sauer Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal Endocrine 27 2005 179 188
2. L.G. Sigurdardottir, U.A. Valdimarsdottir, and K. Fall Circadian disruption, sleep loss, and prostate cancer risk: a systematic review of epidemiologic studies Cancer Epidemiol Biomarkers Prev 21 2012 1002 1011
3. R.M. Moretti, M.M. Marelli, R. Maggi, D. Dondi, M. Motta, and P. Limonta Antiproliferative action of melatonin on human prostate cancer LNCaP cells Oncol Rep 7 2000 347 351
4. C. Bartsch, H. Bartsch, A. Schmidt, S. Ilg, K.H. Bichler, and S.H. Flüchter Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations Clin Chim Acta 209 1992 153 167
5. C.J. Bojkowski, M.E. Aldhous, and J. English Suppression of nocturnal plasma melatonin and 6-sulphatoxymelatonin by bright and dim light in man Horm Metab Res 19 1987 437 440
6. L.G. Sigurdardottir, U.A. Valdimarsdottir, and L.A. Mucci Sleep disruption among older men and risk of prostate cancer Cancer Epidemiol Biomark Prev 22 2013 872 879
7. S.Y.W. Shiu, I.C. Law, K.W. Lau, P.C. Tam, A.W.C. Yip, and W.T. Ng Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype J Pineal Res 35 2003 177 182
8. K. Straif, R. Baan, and Y. Grosse Carcinogenicity of shift-work, painting, and fire-fighting Lancet Oncol 8 2007 1065 1066
9. E.E. Flynn-Evans, L. Mucci, R.G. Stevens, and S.W. Lockley Shiftwork and prostate-specific antigen in the National Health and Nutrition Examination Survey J Natl Cancer Inst 105 2013 1292 1297
10. M. Feychting, B. Osterlund, and A. Ahlbom Reduced cancer incidence among the blind Epidemiol Camb Mass 9 1998 490 494